Log In
Forgot username? Forgot password? New User? Sign Up Free
SCCM is performing maintenance on its websites. For the best browsing experience, please use Microsoft Edge or Safari. Those using Chrome or Firefox may experience access issues at this time.
Tag Search
From Critical Care Medicine In this Editorial the authors write an accompanying piece to Mesotten et al.
Through this program, people are able to get tested and – if they are positive and treatments are appropriate for them – receive a prescription from a health care provider, and have their prescription filled all at one location. These “One-Stop Test to Treat” sites are available at hundreds of locations nationwide, including pharmacy-based clinics, Health Resources Services Administration (HRSA)-supported federally-qualified health centers (FQHCs), and long-term care facilities. People can continue to be tested and treated by their own health care providers who can appropriately prescribe these oral antivirals at locations where the medicines are distributed.
From Critical Care Explorations The authors investigate microvascular function in patients with critical coronavirus disease 2019.
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of bebtelovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg): with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.
The national map below displays public locations that have received shipments of U.S. Government-procured COVID-19 therapeutics under U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) authority. The locations displayed in the locator have reported stock on hand within the last day.
Medicare & COVID-19 Monoclonal Antibody Products: Coverage, Coding, Payment and Billing. Monoclonal antibody products to treat Coronavirus disease 2019 (COVID-19) help the body fight the virus or slow the virus’s growth. Medicare beneficiaries have coverage without beneficiary cost sharing for these products when used as authorized or approved by the Food and Drug Administration (FDA).
The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform, and is updated regularly as new evidence emerges.
December 22, 2021, the FDA issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.
The FDA has granted molnupiravir emergency use authorization (EUA) to treat mild to moderate COVID-19 in adults at high risk of severe illness. High risk people include adults aged 65 and over and people with certain medical conditions. The FDA also states that molnupiravir should only be used when other COVID-19 treatments are unavailable.
This webinar covers highlights from the Critical Impact: Clinical Practice course.
This community developed resource is a quick reference guide for utlization of various COVID-19 pharmacotherapies.
From Critical Care Medicine. In this Review Article the authors established a uniform data collection process required to perform an assessment of any agent type using review criteria that were identified and differentially weighted for each agent class,
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on September 8, 2021
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on August 11, 2021
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on July 14, 2021
From Critical Care Explorations. In this study, the authors found that low-dose methylprednisolone was associated with reduced mortality if given greater than 7 days from onset of symptoms, and no additional benefit greater than 14 days; high dose was associated with higher mortality.
This resource details monoclonal antibody treatments that can be used to treat COVID-19. This is SCCM curated COVID-19 microlearning content.
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on June 9th, 2021
From Critical Care Medicine. In this study, the authors found that the he institution of nonpharmaceutical interventions was associated with a significant decrease in elective and acute ICU admissions and ICU resource use. These findings may help hospitals and health authorities planning for surge capacities and elective surgery management in future pandemics.
From Critical Care Medicine. This Online Letter to the Editor was written in response to an article by Santoro et al. entitled “Anticoagulation Therapy in Patients With Coronavirus Disease 2019: Results From a Multicenter International Prospective Registry (Health Outcome Predictive Evaluation for Corona Virus Disease 2019 [HOPE-COVID19]).”
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on May 12th, 2021
This resource details an the usage of tocilizumab as a treatment for severe COVID-19. This is SCCM curated COVID-19 microlearning content.
From Critical Care Medicine. This online letter to the editor was written in response to “Reversal of the Pathophysiological Responses to Gram-Negative Sepsis by Megadose Vitamin C” by Lankadeva et al
From Critical Care Medicine. This is an online Letter to the Editor in response to the article by Fernandez et al. “Plasma Exchange: An Effective Rescue Therapy in Critically Ill Patients With Coronavirus Disease 2019 Infection.”
From Critical Care Explorations. In this retrospective case series of 29 patients, the authors demonstrated efficacy of extracorporeal Co2 removal using the Hemolung Respiratory Assist System to improve respiratory acidosis in patients with severe hypercapnic respiratory failure due to coronavirus disease 2019.
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on February 24, 2021
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on February 24, 2021.
This resource details the role of aspirin when treating COVID-19 patients.
From Critical Care Medicine. The authors believe that the findings of this study provide a rationale to consider plasma exchange as a therapeutic option in COVID-19 and to include von Willebrand factor and ADAMTS13 in the diagnostic workup.
From SCCM's 50th Critical Care Congress. Learn more about the guidelines therapeutics update and the methodology and its application to public health emergencies.
SCCM’s COVID-19 Rapid Resource Center now links to pertinent content from the Infectious Diseases Society of America (IDSA) COVID-19 Real-Time Learning Network. These resources are categorized as Pharmacology
This resource details the post-hospital treament of pain. This is SCCM curated COVID-19 microlearning content.
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on January 13, 2021.
Two recent trials suggest that immune-damping drugs such as tocilizumab may reduce mortality in patients with severe COVID-19.
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on December 9, 2020.
From Critical Care Explorations In this study, the authors found that patients with coronavirus disease 2019 acute respiratory distress syndrome experienced a higher rate of propofol-associated hypertriglyceridemia than noncoronavirus disease 2019 acute respiratory distress syndrome patients, even after accounting for differences in propofol administration.
From Critical Care Explorations The authors present a case series of eleven patients, five treated with camostat mesylate and six treated with hydroxychloroquine.
From Critical Care Explorations The authors assessed the impact of tocilizumab therapy and found that it was associated with significantly improved survival in coronavirus disease 2019 patients.
From Critical Care Medicine The authors invesitated the safety and efficacy of megadose sodium ascorbate in sepsis.
From Critical Care Explorations The authors conducted a multicenter cohort study to determine the effect of drug therapies on survival in mechanically ventilated patients with coronavirus disease 2019.
From Critical Care Explorations The authors found that mechanical ventilation was significantly associated with odds of delirium even after adjustment for sedatives.
From Critical Care Explorations The authors discuss optimizing continuous renal replacement therapy circuit survival in coronavirus disease 2019 patients admitted to the ICU.
From Critical Care Explorations The authors characterize outcomes associated with high-flow nasal oxygen use in critically ill adult patients with coronavirus disease 2019-associated acute hypoxemic respiratory failure.
From Critical Care Explorations In this study, the authors evaluated the efficacy and safety of inhaled epoprostenol and inhaled nitric oxide in patients with refractory hypoxemia secondary to coronavirus disease 2019.
From Critical Care Explorations The authors investigated the safety and effects of nebulized DAS181 on hypoxic coronavirus disease 2019 patients.
From Critical Care Explorations The authors evalute the use of isoflurane in patients with coronavirus disease 2019–induced acute respiratory distress syndrome.
From Critical Care Medicine The authors assessed the effect of almitrine, a selective pulmonary vasoconstrictor, on arterial oxygenation in severe acute respiratory syndrome coronavirus 2-induced acute respiratory distress syndrome.
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on November 4, 2020.
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on August 12, 2020.
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on October 14, 2020.
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on September 9, 2020.
During this 1-hour activity expert faculty from the American Society of Health-System Pharmacists and the Society of Critical Care Medicine discussed the use of vitamins as adjunctive treatment in patients with COVID-19 as well as the role of Renin-Angiotensin System Inhibition in COVID-19 patients.
From Critical Care Explorations. In this study, the authors found that angiotensin-II treatment for coronavirus disease 2019–induced distributive shock was associated with rapid improvement in multiple physiologic indices and that angiotensin-II in coronavirus disease 2019–induced shock warrants further study.
From Critical Care Explorations. In this observational study, the authors concluded that extracorporeal membrane oxygenation retrieval can rescue young, previously healthy patients with severe coronavirus disease 2019 in whom all the conventional respiratory measures have failed and found that thrombotic and hemorrhagic complications are frequent in this cohort.
From Critical Care Medicine. In this Letter to the Editor, the authors report an update to a previous study, finding a decline in mortality rates in critically ill patients with COVID-19.
From Critical Care Explorations. In this study, the authors examined the outcomes of critically ill coronavirus disease 2019 patients treated with tocilizumab and factors associated with clinical improvement.
From Critical Care Explorations. In this case report, the authors report a series of four critically ill pediatric patients with acute respiratory failure who received coronavirus disease 2019 convalescent plasma as a treatment strategy for severe disease.
From Critical Care Explorations. In this study, the authors gathered available published resources including physicochemical and pharmacokinetic properties and suggest antiviral drug dosing adaptation for coronavirus disease 2019–infected critically ill patients receiving extracorporeal therapy.
The increase in acute kidney injury in COVID-19 patients is resulting in more utilization of renal replacement therapy (RRT) and continuous renal replacement therapy (CRRT).
From Critical Care Medicine. The authors present some common features shared by severe coronavirus disease 2019 patients and sepsis and describe proposed anti-inflammatory therapies for coronavirus disease 2019 which have been previously evaluated in sepsis.
From Critical Care Medicine. In this single center study, the authors found that plasma exchange mitigates cytokine storm, reverses organ failure, and could improve survival in critically ill patients with coronavirus disease 2019 infection.
From Critical Care Explorations. The authors found that thrombosis profiling identified endothelial activation and glycocalyx degradation in coronavirus disease 2019 positive patients and believe that the data from this study suggest that medications to protect and/or restore the endothelial glycocalyx, as well as platelet inhibitors, should be considered for further study.
From Critical Care Explorations. In this study of three patients, the authors state that their findings suggest that high doses of dexmedetomidine infusion are associated with hyperpyrexia in a seemingly dose-dependent fashion in critically ill patients with coronavirus disease 2019.
From Critical Care Medicine. In this study, the authors state their data suggest that a ""higher” positive end-expiratory pressure approach in patients with severe acute respiratory syndrome coronavirus 2 acute respiratory distress syndrome and high compliance improves oxygenation and lung aeration but may result in alveolar hyperinflation and hemodynamic alterations.
From Critical Care Explorations. The authors sought to determinewhether placental cell therapy PLacental eXpanded (PLX)-PAD (Pluristem Therapeutics, Haifa, Israel) was beneficial to treating critically ill patients suffering from acute respiratory distress syndrome due to coronavirus disease 2019.
From Critical Care Medicine. In this Editorial, the authors discuss the challenges of caring for patients with COVID-19 without evidence to guide them through the lens of high-flow nasal oxygenation and how there have been slow changes for improvement.
From Critical Care Explorations. In this Letter to the Editor, the authors describe their experience with a series of eight patients receiving adjunct therapeutic plasma exchange for severe coronavirus disease pneumonia complicated by sepsis with multiple organ dysfunction in which C-reactive protein and ferritin levels significantly decreased with therapeutic plasma exchange, whereas D-dimer decreased to a lesser degree.
From Critical Care Explorations. In this narrative review, the authors summarize existing knowledge of the immune response to coronavirus infection and highlight the current and potential future roles of therapeutic strategies to combat the hyperinflammatory response of patients with coronavirus disease 2019.
From Critical Care Explorations. In this article, the authors describe the intracranial pressure dynamics and cerebral vasomotor reactivity in a coronavirus disease 2019 patient with acute encephalitis treated with cerebrospinal fluid drainage and therapeutic plasma exchange.
This presentation is a review of the renin-angiostensin System and COVID-19. This is SCCM curated COVID-19 microlearning content.
The Society of Critical Care Medicine (SCCM) and the American Society of Health-System Pharmacists (ASHP) in their third series of therapeutic debates in the management of COVID-19.
ASHP and the SCCM teamed up in their second series of therapeutic debates in the management of COVID-19. In the first debate, the content matter experts reviewed the latest literature and debate the use of steroids for treatment of COVID-19.
From Critical Care Medicine. The authors report on a sedation and ventilation method used in France.
From Critical Care Medicine. The authors reviewed thromboelastography studies in critically ill patients with coronavirus disease 2019 to characterize their coagulation states.
From Critical Care Medicine. This Letter to the Editor is in response to an article by Iba et al. (Coagulopathy of Coronavirus Disease 2019) and discusses dosing recommendations of low molecular weight heparin.
From Critical Care Explorations. In this Letter to the Editor, the authors report their adapted thromboprophylaxis practice of low-molecular-weight heparin administration in coronavirus disease 2019 ICU patients.
This resources detail how to manage drug shortages for alternative analgesics and sedagent agents. This is SCCM curated COVID-19 microlearning content.
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on July 8th, 2020.
From Critical Care Explorations. The authors report a case of peripheral arterial thrombosis associated with COVID-19, resulting in acute limb ischemia of the right lower extremity.
From Critical Care Explorations. This articles describes the outcomes with use of a combination of tocilizumab and 34 methylprednisolone administered around the time of endotracheal intubation in patients with 35 confirmed COVID-19-associated hypoxemic respiratory failure requiring mechanical ventilation.
From Criticial Care Explorations. The authors report on the use of corticosteroids in mechanically ventilated patients with SARSCoV-2 related acute respiratory distress syndrome.
In this question and answer webcast, attendees had the opportunity to post questions about managing critically ill patients with COVID-19 and other issues. Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were also addressed. Webcast held on June 19, 2020
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on June 10th, 2020.
This webcast series engages a panel of critical care experts who will address questions from non-ICU clinicians caring for critically ill patients during the COVID-19 pandemic. Participants are encouraged to ask about any related topics at the time of registration or live during the session.
This webinar debate will cover immunomodulatory therapies and approaches to anticoagulation in patients with COVID-19. Each debate will be moderated by the Society of Critical Care Medicine (SCCM) and American Society of Health-System Pharmacists (ASHP) Presidents.
This presentation provides an overview of strategies for triaging analgesic, sedative, and paralytic agents patients with COVID-19. This is SCCM curated COVID-19 microlearning content.
This presentation provides an overview of the types of strategies for enhancing sleep in patients with COVID-19. This is SCCM curated COVID-19 microlearning content.
This presentation covers how to manage neuromuscular blocking agent (NMBA) shortages. This is SCCM curated COVID-19 microlearning content.
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on May 13th, 2020.
From Critical Care Medicine. Recent studies have reported a high incidence of thrombotic events in COVID-19. However, the significance of thromboembolic complications has not been widely appreciated. The purpose of this review is to provide current knowledge of this serious problem.
From Critical Care Medicine. The authors sought to determine the frequency of venous thromboembolism in critically ill coronavirus disease 2019 patients and associate a degree of inflammatory marker elevation to venous thromboembolism development. They found that routine chemical venous thromboembolism prophylaxis may be inadequate in preventing venous thromboembolism in severe coronavirus disease 2019.
In this question and answer webcast series, attendees had an opportunity to pose questions about managing critically ill patients with COVID-19 and other issues.
From Critical Care Explorations. A letter to the editor in response to Villar et al. article on corticosteroids and COVID-19.
This webcast was an SCCM COVID-19 expert panel discussion comparing the Surviving Sepsis Campaign COVID-19 Guidelines with the newly released National Institutes of Health Coronavirus (COVID-19) Treatment Guidelines.
This joint webinar was moderated by the Society of Critical Care Medicine (SCCM) and the American College of Emergency Physicians (ACEP) Presidents, along with invited experts from both societies, to address difficult questions regarding managing COVID-19 patients.
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered.
From Critical Care Explorations. A letter to the editor of Critical Care Explorations about SSC COVID-19 Guidelines and the need to update these guideines and others regularly to help universally optimize sepsis care due to COVID-19 and help flatten the briskly rising morbidity and mortality curve.
From Critical Care Explorations. The authors state that inconclusive clinical evidence should not be a reason for abandoning CST in COVID-19-associated ARDS.
Steve Pastores, MD, co-author of the Critical Care Explorations article "Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019," answers question regarding the use of corticosteriod treatment for ARDS caused by COVID-19. This is SCCM curated COVID-19 microlearning content.
Steve Pastores, MD, co-author of the Critical Care Explorations article "Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019," discusses the timing, dosing and duration recommendations for the use of corticosteriod treatment for COVID-19. This is SCCM curated COVID-19 microlearning content.
Steve Pastores, MD, co-author of the Critical Care Explorations article "Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019," discusses the disparities in the use of corticosteriod treatment for ARDS caused by COVID-19 by different organizations. This is SCCM curated COVID-19 microlearning content.
Steve Pastores, MD, co-author of the Critical Care Explorations article "Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019," discusses the use of corticosteriod treatment for ARDS caused by COVID-19. This is SCCM curated COVID-19 microlearning content.
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on April 15, 2020.
This interactive webinar focused on key elements of critical care pharmacotherapy and pharmacy operations in the SARS-CoV-2 pandemic.
Explore the Surviving Sepsis Campaign’s Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) (Alhazzani W, et al. Crit Care Med. 2020 Mar 27; Epub ahead of print) with host Kyle B. Enfield, MD, and authors Mitchell M. Levy, MD, MCCM, and Waleed Alhazzani, MD, MSc, FRCPC.
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Question and Answer Webcast Series - Webcast 2 held on April 10, 2020.
COVID-19 Guideline Resource. SCCM has released its Surviving Sepsis Campaign COVID-19 guidelines to manage critically ill adults with COVID-19 in the intensive care unit (ICU).
This presentation is an overview of symptoms, diagnosis and mortality concerns seen when treating pediatric patients with COVID-19. This is SCCM curated COVID-19 microlearning content.
COVID-19 - - Quick Reference Chart. This chart is to be used as a rapid resource when choosing therapeutic options for treating COVID-19 patients.
COVID-19 Guideline Resource.
Webcast participants were able to learn more about the recommendations included in the guidelines regarding infection control, laboratory diagnosis and specimens, hemodynamic support, ventilatory support